X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES AJANTA PHARMA SUVEN LIFESCIENCES/
AJANTA PHARMA
 
P/E (TTM) x 17.6 21.1 83.8% View Chart
P/BV x 3.6 3.7 96.3% View Chart
Dividend Yield % 0.6 0.9 62.1%  

Financials

 SUVEN LIFESCIENCES   AJANTA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
AJANTA PHARMA
Mar-19
SUVEN LIFESCIENCES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3381,422 23.7%   
Low Rs169898 18.9%   
Sales per share (Unadj.) Rs52.1233.5 22.3%  
Earnings per share (Unadj.) Rs6.844.0 15.5%  
Cash flow per share (Unadj.) Rs8.652.2 16.4%  
Dividends per share (Unadj.) Rs1.509.00 16.7%  
Dividend yield (eoy) %0.60.8 76.2%  
Book value per share (Unadj.) Rs65.3255.1 25.6%  
Shares outstanding (eoy) m127.2888.02 144.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.95.0 97.9%   
Avg P/E ratio x37.126.4 140.7%  
P/CF ratio (eoy) x29.622.2 133.0%  
Price / Book Value ratio x3.94.5 85.4%  
Dividend payout %22.020.5 107.3%   
Avg Mkt Cap Rs m32,272102,081 31.6%   
No. of employees `0001.16.8 15.9%   
Total wages/salary Rs m6614,307 15.4%   
Avg. sales/employee Rs Th6,132.23,022.6 202.9%   
Avg. wages/employee Rs Th611.1633.4 96.5%   
Avg. net profit/employee Rs Th803.5569.1 141.2%   
INCOME DATA
Net Sales Rs m6,63520,554 32.3%  
Other income Rs m242211 114.9%   
Total revenues Rs m6,87720,765 33.1%   
Gross profit Rs m1,6045,664 28.3%  
Depreciation Rs m221721 30.7%   
Interest Rs m3812 325.0%   
Profit before tax Rs m1,5875,143 30.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,273 56.4%   
Profit after tax Rs m8693,870 22.5%  
Gross profit margin %24.227.6 87.7%  
Effective tax rate %45.224.8 182.7%   
Net profit margin %13.118.8 69.6%  
BALANCE SHEET DATA
Current assets Rs m6,23211,812 52.8%   
Current liabilities Rs m1,4903,776 39.5%   
Net working cap to sales %71.539.1 182.8%  
Current ratio x4.23.1 133.7%  
Inventory Days Days8677 111.7%  
Debtors Days Days8382 101.2%  
Net fixed assets Rs m4,04314,398 28.1%   
Share capital Rs m127175 72.6%   
"Free" reserves Rs m8,18322,277 36.7%   
Net worth Rs m8,31022,452 37.0%   
Long term debt Rs m187 269.7%   
Total assets Rs m10,38926,962 38.5%  
Interest coverage x43.1444.3 9.7%   
Debt to equity ratio x00 728.7%  
Sales to assets ratio x0.60.8 83.8%   
Return on assets %8.714.4 60.7%  
Return on equity %10.517.2 60.7%  
Return on capital %19.523.0 85.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62210,682 52.6%   
Fx outflow Rs m1,7992,102 85.6%   
Net fx Rs m3,8228,580 44.6%   
CASH FLOW
From Operations Rs m3563,748 9.5%  
From Investments Rs m-279-2,228 12.5%  
From Financial Activity Rs m-225-1,475 15.3%  
Net Cashflow Rs m-14845 -327.9%  

Share Holding

Indian Promoters % 63.4 73.8 85.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.0 214.7%  
Shareholders   37,287 20,968 177.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   BIOCON   WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Passenger Vehicles Sales Data, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure yesterday and ended their session deep in the red. At the closing bell yesterday, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 21, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS